Heron Therapeutics (NASDAQ:HRTX) announces results from EPOCH 2 follow-on study evaluating the efficacy and safety of locally administered HTX-011 300 mg bupivacaine / 9 mg meloxicam into the surgical site in combination with a postoperative non-opioid multimodal analgesia regimen of over-the-counter oral acetaminophen and ibuprofen in 63 patients undergoing open inguinal hernia repair surgery.
In in this study, more than 90% of patients did not require opioids to manage their postoperative pain during the first 72 hours.
87% of patients were opioid-free through Day 10 and 83% throughout the entire 28-day follow-up period of the study.
Mean pain intensity scores were similar between cohorts and never rose above the mild pain range (NRS <4) throughout the 72-hour postoperative period.
Addition of an intraoperative dose of ketorolac did not provide additional benefit for pain intensity or opioid use.
HTX-011 was well tolerated, with a safety profile comparable to placebo and bupivacaine solution.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.